IgA肾病发病机制研究进展  

Research advances on the pathogenesis of IgA nephropathy

作　　者：鲁芳草 袁红伶 Lu Fang-cao;Yuan Hong-ling(Department of Nephrology,First Affiliated Hospital,Kunming Medical University,Kunming 650000,China)

机构地区：[1]昆明医科大学第一附属医院肾脏内科,昆明650000

出　　处：《临床肾脏病杂志》2022年第2期166-171,共6页Journal Of Clinical Nephrology

基　　金：云南省卫生和计划生育委员会医学领军人才培养计划(L-201606)。

摘　　要：IgA肾病仍是目前世界范围内最常见的原发性肾小球疾病,有高达20%~40%的患者在肾活检确诊后的20年内进展为终末期肾病,目前针对该病的治疗主要是支持疗法和免疫抑制治疗,而深入了解疾病的发病机制是有效治疗该病的关键,关于其发病机制的研究一直是肾脏病领域的热点之一。本文围绕目前主流的IgA肾病发病的"四重打击"学说进行综述,并对参与发病的IgA受体及激活的补体途径进行探讨,为临床进一步探索IgA肾病治疗靶点提供理论依据。IgA nephropathy is the most common primary glomerular disease in the world. Up to20%-40% of patients develop end-stage renal disease within 20 years after a definite diagnosis of renal biopsy. Current managements of this disease include supportive measures and immunosuppressive therapy.Since an in-depth understanding of its pathogenesis is vital for its effective treatment,researches on the pathogenesis of IgA nephropathy has been a major hotspot in the field of kidney diseases. This review summarized the mainstream theory of "quadruple blow" and focused upon IgA receptors and activated complements in the pathogenesis of IgA nephropathy. It was intended to provide theoretical rationales for further clinical exploring therapeutic targets for IgA nephropathy.

关 键 词：IGA肾病 丰乳糖缺陷型-IgA1 受体 Fc 受体 转铁蛋白 替代途径 凝集素途径 

分 类 号：R692.31[医药卫生—泌尿科学]